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A 23-month-old child with leukemia who was receiving chemotherapy developed fevers. Serial blood cultures
from a central venous catheter and a peripheral venous site grew an organism identified by 16S rRNA gene
sequencing and phenotypic analysis as Nocardia higoensis, an opportunistic organism isolated once previously
from a pulmonary infection in Japan.
CASE REPORT
A 23-month-old male child with B-cell acute lymphocytic
leukemia (ALL) was being treated with a maintenance chemo-
therapy regimen that included methotrexate, 6-mercaptopu-
rine, and pegaspargase. He had a Broviac central venous cath-
eter (CVC) that was used for intravenous (i.v.) access with his
chemotherapy. Despite his illness, he was an active child with-
out a history of previous or recurrent infections. Two days
prior to hospital admission he developed fevers of up to
39.4°C, and blood cultures were obtained (BD Bactec 9240
blood culture instrument and BD Bactec Peds Plus media
bottles; Becton Dickinson, Franklin Lakes, NJ) from the cen-
tral venous line at a referring hospital. He was treated empir-
ically with i.v. ceftriaxone and monitored as an outpatient. The
blood cultures became positive at about 48 h of incubation for
growth of a Gram-positive bacillus that could not be identified
by the referring hospital. He was subsequently admitted to St.
Louis Children’s Hospital (St. Louis, MO) and was adminis-
tered broad-spectrum antibiotic therapy with i.v. vancomycin
and i.v. cefepime.
The complete blood count (CBC) at the time of admission
included a white blood cell count of 4.7  109 cells/liter (ref-
erence range, [6.0 to 17.0] 109 cells/liter), hemoglobin of 10.3
g/dl (reference range, 10.5 to 13.5 g/dl), and a platelet count of
244  109 cells/liter (reference range, [144 to 440]  109
cells/liter). He was not neutropenic (absolute neutrophil count,
3.9  109 cells/liter; reference range for a healthy child, [1.0 to
10.0]  109 cells/liter), but he was lymphopenic (absolute lym-
phocyte count, 0.47  109 cells/liter; reference range, [1.2 to
11.5]  109 cells/liter). A complete metabolic panel was nor-
mal, with no evidence of liver or renal dysfunction. He was
febrile with an ill appearance but maintained normal blood
pressure and normal mental status, and there was no concern
for sepsis. Isolator blood cultures (Wampole) were obtained
from his Broviac catheter, plated on sheep blood agar and
chocolate agar, and were positive for growth at 24 to 48 h of
incubation. A modified Kinyoun stain (12) identified the pres-
ence of a beaded, partially acid-fast organism that initially grew
as short rods but upon extended incubation on sheep blood
agar (72 h) exhibited colonies with salmon-red pigment and
aerial hyphae and microscopically exhibited longer, filamen-
tous morphology with branching. Based on these characteris-
tics, the organism was presumed to be a rapidly growing My-
cobacterium or Nocardia species. Empirical antibiotic therapy
was changed to oral clarithromycin and i.v. imipenem, awaiting
further identification and susceptibility testing. A total of seven
positive blood cultures were obtained over a period of 6 days,
including five Isolator blood cultures from the Broviac catheter
and two cultures obtained from a peripheral venous site. The
BD Bactec FX blood culture instrument and Bactec Peds Plus
and anaerobic lytic/F medium (Becton Dickinson) were used
for peripheral blood cultures. The infected Broviac catheter
was removed, and peripheral blood cultures remained positive
for growth of this organism for 24 h after catheter removal
before becoming sterile. The patient became afebrile following
removal of the infected catheter and remained afebrile for the
remainder of his hospitalization. Magnetic resonance imaging
(MRI) of his brain and computed tomography (CT) imaging of
his chest, abdomen, and pelvis identified no definitive evidence
of disseminated infection.
In order to expedite identification of the organism to
optimize antimicrobial therapy, 16S rRNA gene sequencing
was performed on the isolate based a laboratory-developed
method. The full-length 16S rRNA gene was amplified using
the primers 27F (AGAGTTTGATCCTGGCTCAG) and 1391R
(GACGGGCGGTGWGTRCA) (3). The product was se-
quenced bidirectionally, and the resulting 1,250 bp of high-
quality sequence were aligned with nucleotide sequences in the
Ribosomal Database Project (RDP) and GenBank by using
BLAST (http://blast.ncbi.nlm.nih.gov/blast.cgi). The result was
100.0% sequence identity to Nocardia higoensis sp. nov., a
Nocardia isolate reported only once previously, in association
with human pulmonary disease in Japan (6). A second closely
related Nocardia species reported by Kageyama et al. (6), N.
shimofusensis sp. nov., was found to have 11 bp mismatches
with our isolate near the 3 end of the gene sequence, with
overall 99.1% sequence identity. The next nearest match was
Nocardia farcinica, with 98.7% sequence homology to our iso-
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late. Both RDP and GenBank provided identical sequence
matches. Biochemical characteristics supported the genetic
identification of the isolate as N. higoensis and matched previ-
ously reported features for that species, including urease ac-
tivity (which is relatively rare in Nocardia spp.), a negative
xanthine decomposition reaction, a negative casein reaction,
and growth in lysozyme broth (6).
The initial study describing N. higoensis and N. shimofusensis
reported that these two species can be differentiated by the
ability to grow at elevated temperatures: N. shimofusensis will
grow at 37°C but not 45°C, whereas N. higoensis will grow at
both temperatures (6). Our isolate grew at 37°C but not at
42°C, suggesting this property may be variable between isolates
of N. higoensis.
Upon extended incubation (5 days), two colony types be-
came evident on blood and chocolate agar media, with en-
hanced morphology on chocolate agar. One was nonpigmented
with a flat, rhizoid morphology, and the other was a salmon-
red, chalky colony with aerial hyphae present. A reddish pig-
mentation is consistent with the colonial morphology previ-
ously reported to occur for N. higoensis sp. nov. (6). 16S rRNA
gene sequencing was then performed on each colony type; they
were found to have identical 16S rRNA gene sequences and
were deemed to be colony variants of the same species. A
laboratory-developed Nocardia genus-specific SYBR green
PCR assay targeting the noc gene was also positive when per-
formed on this organism. The finding that both colony types
exhibited identical melting curves provided additional evi-
dence that these were colony variants of an identical species.
Antibiotic susceptibilities among isolates within the genus
Nocardia are quite unpredictable, and therefore, identification
to the species level may be helpful in determining appropriate
empirical antibiotic therapy. As very little is known regarding
the typical antimicrobial susceptibility profile for N. higoensis,
the isolate was sent to the Mycobacterial/Nocardia Research
Laboratory at the University of Texas Health Center for iden-
tification and susceptibility testing. The isolate was identified
as “Nocardia spp.” by this laboratory; DNA sequence analysis
was not repeated at the Texas lab, and further identification to
the species level was not reported. Nocardia susceptibility test-
ing was performed using Kirby-Bauer disk diffusion and broth
microdilution utilizing previously published methods (16, 17).
The susceptibility profiles of the two colony types were iden-
tical; the results are summarized in Table 1.
While we awaited susceptibility testing results, empirical an-
tibiotic therapy for the patient was modified to i.v. imipenem
plus amikacin. After 7 days, oral sulfadiazine was substituted
for the amikacin, and the patient received three additional
weeks of imipenem and oral sulfadiazine. At that time, sus-
ceptibility test results were available, and based on those re-
sults, clarithromycin was substituted for imipenem. The oral
regimen of sulfadiazine and clarithromycin was continued for
the patient, to complete a 6-month course of treatment. This
duration was chosen based on his need for ongoing chemo-
therapy and theoretical risk of relapse. He has not since had
any further episodes of bacteremia or evidence of relapse of his
infection.
Nocardia spp. are classified within the family Nocardiaceae,
suborder Corynebacteriaceae, order Actinomycetales. Nocardia
is an aerobic, branching, partially acid-fast bacillus with a high
GC DNA content. Nocardia is ubiquitous in the environment
as a saprophytic component in soil, sand, fresh and salt water,
and decaying organic matter (1). Taxonomic classification of
Nocardia has historically been confusing and remains contro-
versial today due to a paucity of biochemical markers to dis-
tinguish closely related species. The introduction of molecular
characterization methods (e.g., 16S rRNA gene sequencing)
TABLE 1. Nocardia higoensis susceptibility testinga
Antibiotic(s)
Kirby-Bauer test Microdilution test
Zone sizeb (mm) Interpretation MIC(s) (g/ml) Interpretation
Amikacin 40 Susceptible 1 Susceptible
Amoxicillin-clavulanate 25 Susceptible 16/8 Intermediate
Ceftriaxone ND 16 Intermediate
Ciprofloxacin 30 Susceptible 0.25 Susceptible
Clarithromycin 40 Susceptible 2 Susceptible
Doxycycline ND 1 Susceptible
Ertapenemc 30 ND
Gentamicin 30 Susceptible ND
Imipenem 40 Susceptible 4 Susceptible
Kanamycin 34 Susceptible ND
Linezolid ND 1 Susceptible
Meropenemc 30 ND
Minocycline ND 1 Susceptible
Moxifloxacin ND 0.25 Susceptible
Tigecyclinec 40 0.5
Tobramycin 30 Susceptible 1 Susceptible
Trimethoprim-sulfamethoxazole ND 0.25/4.75 Susceptible
a Susceptibility testing was performed by the Mycobacterial/Nocardia Research Lab (Director, Richard Wallace), University of Texas Health Center (Tyler, TX). ND,
not determined. The methods for Kirby-Bauer disk diffusion susceptibility and broth microdilution MIC determinations have been previously published (16, 17).
b The broth MIC is the only susceptibility method approved for Nocardia isolates by the Clinical and Laboratory Standards Institute (previously known as the NCCLS)
(14).
c There are currently no CLSI standard MIC breakpoints for ertapenem, meropenem, or tigecycline for Nocardia and, therefore, there are no interpretation criteria
available for disk diffusion or microdilution results.




arch 12, 2014 by W






has improved the resolution of species-level identification. The
genus Nocardia currently encompasses more than 80 published
species in the NCBI Taxonomy Database as of August 2010.
Not all of these species have been rigorously characterized by
genetic and/or biochemical profiling, and thus the taxonomy of
this genus remains in a state of flux.
Nocardia species can colonize skin and the upper respiratory
tract without causing disease. Given the ubiquitous presence of
Nocardia in the environment, it can be difficult at times to
attribute infection to Nocardia spp. when these organisms are
isolated from some specimen types. However, several species
of Nocardia are known pathogens of humans and animals.
Human infections in which Nocardia is a recognized pathogen
most commonly occur in immunocompromised hosts and typ-
ically manifest as severe pulmonary disease or central nervous
system infections (e.g., brain abscess or meningitis) (1, 2, 4, 6,
11, 13). Local infections caused by traumatic inoculation can
occur in otherwise-healthy individuals. Deficiencies in cell-me-
diated immunity, such as in cancer patients receiving steroids
and/or chemotherapy, transplant recipients on immunosup-
pressive regimens, and those with AIDS through infection with
human immunodeficiency virus (HIV), place individuals at
particular risk of invasive and disseminated nocardiosis (2, 4–6,
9, 11, 13, 15). The one patient previously reported to have
disease from which N. higoensis was first isolated was a 70-year-
old female from Japan on steroid therapy for autoimmune
hepatitis, and she developed Nocardia pulmonary infection (6).
Bacteremia with Nocardia species is relatively uncommon,
but when associated with disseminated infection it has a rela-
tively high mortality rate. In a previous review of 36 cases of
Nocardia bacteremia, Kontoyiannis et al. reported a mortality
rate of about 50%; the presence of endovascular foreign bodies
(i.e., indwelling catheters) was a major risk factor associated
with developing Nocardia bacteremia (8). Fortunately, cathe-
ter-related infection with Nocardia bacteremia occurs at a low
frequency; about 7% of all invasive Nocardia infections in a
study at the University of Texas M.D. Anderson Cancer Center
involved central venous catheters (15). CVC-associated bacter-
emia has been associated with a more benign clinical course.
Good outcomes have occurred with early removal of the in-
fected catheter and prompt initiation of antibiotic therapy (5,
15). A case series by Kontoyiannis et al. reported resolution of
bacteremia in three patients whose CVCs were discontinued in
addition to antibiotic treatment of 2 weeks to 3 months dura-
tion. In contrast, a single patient who received 4 weeks of
antibiotic therapy but did not have the CVC removed experi-
enced relapse of infection 4 months later with repeat bacter-
emia in addition to pulmonary disease (7). The absolute re-
quirement to remove a Nocardia-infected catheter and the
optimal duration of antibiotic therapy have been debated by
others and, currently, no clear guidelines have been established
(5, 10).
The present case involves Nocardia higoensis, a species iso-
lated once previously from pulmonary disease in an immuno-
compromised female in 2001 in Japan (6). To our knowledge,
this is the first documented case of bacteremia with N. higoen-
sis. Our patient did have clinical risk factors, including leuke-
mia with chemotherapy and concurrent lymphocytopenia and
an indwelling CVC, which may have predisposed him to infec-
tion. It is possible he acquired this Nocardia infection from
environmental contamination of his Broviac catheter with dust
or dirt while playing. Removal of the infected catheter resulted
in clearance of the bacteremia within 24 h, after several days of
serially positive blood cultures. Empirical antibiotic therapy
was modified quickly based on information provided by mo-
lecular identification with 16S rRNA gene sequencing. This
case illustrates the utility of this technique in identification of
bacteria, particularly those isolated from immunosuppressed
patients, in which the isolation of “unusual” microorganisms
(which might not be identifiable by conventional phenotypic
methods) is not uncommon.
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